Social vulnerability and clinical trial enrollment: the next frontier of health equity.
3/5 보강
TL;DR
Neighborhood social vulnerability is a barrier to cancer clinical trial enrollment, especially among NH Black patients, and focused interventions targeting education, transportation, and neighborhood resources may increase equity.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
566 patients, 36 456 (1.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Neighborhood social vulnerability is a barrier to cancer clinical trial enrollment, especially among non-Hispanic Black patients. Focused interventions targeting education, transportation, and neighborhood resources may increase equity.
OpenAlex 토픽 ·
Food Security and Health in Diverse Populations
Health disparities and outcomes
Migration, Health and Trauma
Neighborhood social vulnerability is a barrier to cancer clinical trial enrollment, especially among NH Black patients, and focused interventions targeting education, transportation, and neighborhood
- p-value P < .0001
- OR 0.80
- 연구 설계 cohort study
APA
Shruthi R. Perati, Sana M. Mohayya, et al. (2026). Social vulnerability and clinical trial enrollment: the next frontier of health equity.. Journal of the National Cancer Institute, 118(4), 721-729. https://doi.org/10.1093/jnci/djaf355
MLA
Shruthi R. Perati, et al.. "Social vulnerability and clinical trial enrollment: the next frontier of health equity.." Journal of the National Cancer Institute, vol. 118, no. 4, 2026, pp. 721-729.
PMID
41423777 ↗
Abstract 한글 요약
[BACKGROUND] Clinical trials drive novel cancer therapies, yet enrollment remains low and unrepresentative of vulnerable groups. Most clinical trial disparities literature examines demographics, excluding social determinants of health. We evaluated the association between social vulnerability and clinical trial enrollment among patients with the 5 leading causes of cancer death and examined how this association varies by race and ethnicity in the United States.
[METHODS] In this retrospective cohort study, the national Vizient Clinical Database was queried for patients with lung, breast, prostate, colorectal or pancreatic cancer from 2022 to 2023. The exposure was the Vizient Vulnerability Index, a novel, healthcare-specific tool assessing census tract-level social vulnerability. The primary outcome was clinical trial enrollment. Multivariable analysis evaluated the association of Vizient Vulnerability Index with clinical trial enrollment, including tests for interaction by race.
[RESULTS] Of 2 660 566 patients, 36 456 (1.4%) enrolled in a clinical trial. Trial participants were more likely to be young, non-Hispanic White, and privately insured and to have metastases. Enrollment odds were lower for patients living in the most vulnerable census tracts (odds ratio [OR] = 0.80, 95% confidence interval [CI] = 0.77 to 0.89) and non-Hispanic Black patients (OR = 0.80, 95% CI = 0.75 to 0.83). Vulnerability in education, transportation, and neighborhood resources was associated with decreased enrollment. High social vulnerability disproportionately impacted enrollment for non-Hispanic Black patients (OR = 0.48, 95% CI = 0.41 to 0.62) compared with non-Hispanic White patients (OR = 0.82, 95% CI = 0.73 to 0.92; P < .0001 for interaction).
[CONCLUSIONS] Neighborhood social vulnerability is a barrier to cancer clinical trial enrollment, especially among non-Hispanic Black patients. Focused interventions targeting education, transportation, and neighborhood resources may increase equity.
[METHODS] In this retrospective cohort study, the national Vizient Clinical Database was queried for patients with lung, breast, prostate, colorectal or pancreatic cancer from 2022 to 2023. The exposure was the Vizient Vulnerability Index, a novel, healthcare-specific tool assessing census tract-level social vulnerability. The primary outcome was clinical trial enrollment. Multivariable analysis evaluated the association of Vizient Vulnerability Index with clinical trial enrollment, including tests for interaction by race.
[RESULTS] Of 2 660 566 patients, 36 456 (1.4%) enrolled in a clinical trial. Trial participants were more likely to be young, non-Hispanic White, and privately insured and to have metastases. Enrollment odds were lower for patients living in the most vulnerable census tracts (odds ratio [OR] = 0.80, 95% confidence interval [CI] = 0.77 to 0.89) and non-Hispanic Black patients (OR = 0.80, 95% CI = 0.75 to 0.83). Vulnerability in education, transportation, and neighborhood resources was associated with decreased enrollment. High social vulnerability disproportionately impacted enrollment for non-Hispanic Black patients (OR = 0.48, 95% CI = 0.41 to 0.62) compared with non-Hispanic White patients (OR = 0.82, 95% CI = 0.73 to 0.92; P < .0001 for interaction).
[CONCLUSIONS] Neighborhood social vulnerability is a barrier to cancer clinical trial enrollment, especially among non-Hispanic Black patients. Focused interventions targeting education, transportation, and neighborhood resources may increase equity.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (2)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.